For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor α (IkBα) is a member of a family of cellular proteins that function to inhibit NF-kB transcription factor. When IkBα is phosphorylated by IKKβ, this prevents IkBα from inhibiting NF-kB which then frees NF-kB and allows it to enter the nucleus of the cell, where it activates various genes involved in inflammation and other immune responses. The IKKβ signaling pathway is associated with numerous therapeutic areas, including diseases such as multiple sclerosis, rheumatoid arthritis, psoriasis, and many types of cancers.
The AlphaLISA SureFire Ultra Human and Mouse Phospho-IkBα (Ser32/36) is a sandwich immunoassay for the quantitative detection of Phospho-IkBα (Ser32/36) in cellular lysates, using Alpha Technology.
|Assay Points (200-50,000)||100 Assay Points|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA SureFire Ultra|
|Shipping Condition||Blue Ice|
|Target Species||Human, Mouse|
|Therapeutic Area||Autoimmunity, Oncology, Immuno-oncology|
|Unit Size||100 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
Find out about our range of integrated solutions for drug discovery screening in this e-brochure.
Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.
Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.
Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.